Astrazeneca (AZN) FCF Margin (2009 - 2026)

Astrazeneca has reported FCF Margin for 18 years, with the latest figure at 23.58% in Q2 2026.

• On a quarterly basis, FCF Margin fell 441.0% year-over-year to 23.58% in Q2 2026; TTM through Jun 2026 was 27.31%, a 78.0% decrease from a year earlier, with the FY2025 full-year figure at 29.65%, up 371.0% from the prior year.
• FCF Margin was 23.58% for Q2 2026 at Astrazeneca, down from 25.68% in the prior quarter.
• The five-year high for FCF Margin was 66.12% in Q4 2022, with the low at 14.12% in Q2 2022.
• Average FCF Margin over 5 years is 28.56%, with a median of 26.24% recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: FCF Margin soared 5098 bps in 2022, then slumped 4159 bps in 2023.
• Over 5 years, FCF Margin stood at 66.12% in 2022, then sank by 63 bps to 24.53% in 2023, then increased by 5 bps to 25.68% in 2024, then retreated by 15 bps to 21.8% in 2025, then increased by 8 bps to 23.58% in 2026.
• The last three FCF Margin figures came in at 23.58% (Q2 2026), 25.68% (Q1 2026), and 21.8% (Q4 2025), per Business Quant data.